Good day, ladies and gentlemen, and welcome to the Q1 2018 Spark Therapeutics, Inc. earnings conference call. [Operator Instructions]. As a reminder, this conference is being recorded. I would now ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Details about how the dispute ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Spark Therapeutics' growth ...

* Spark Therapeutics Inc - Co transferring enhanced SPK-9001 manufacturing process to Pfizer * Spark Therapeutics - Co, Pfizer ‍have entered into amendment to their license agreement for SPK-9001 * ...

A company's journey from launch to acquisition is rarely a straight path. It involves overcoming many challenges and obstacles, especially for a pioneering gene therapy company. In this special report ...

CRF acquired Spark Therapeutics, Inc.’s SPK-7001 CHM gene therapy assets and is analyzing long-term data to identify key clinical measures for development ...

Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, ...

Please join us for a Gene Therapy Symposium that will convene faculty and researchers from Drexel University and Spark Therapeutics to present the latest developments in gene therapies research and ...

Spark Therapeutics Inc. said it would charge $850,000 a patient for a pioneering new treatment for a hereditary form of vision loss—below the $1 million price tag the company had considered, but still ...

The University City Science Center building. Two new people were appointed to life sciences leadership roles last month. Local cell and gene therapy success story Spark Therapeutics announced its next ...

The FDA approved a new gene therapy to treat an inherited form of vision loss that may result in blindness. The drug, by Spark Therapeutics (Nasdaq: ONCE), is called Luxturna (voretigene ...